Logo image of NXL

NEXALIN TECHNOLOGY INC (NXL) Stock Fundamental Analysis

NASDAQ:NXL - Nasdaq - US65345B2016 - Common Stock - Currency: USD

1.21  +0.01 (+0.83%)

After market: 1.19 -0.02 (-1.65%)

Fundamental Rating

3

Overall NXL gets a fundamental rating of 3 out of 10. We evaluated NXL against 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NXL as it has an excellent financial health rating, but there are worries on the profitability. NXL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NXL has reported negative net income.
NXL had a negative operating cash flow in the past year.
In the past 5 years NXL always reported negative net income.
In the past 5 years NXL always reported negative operating cash flow.
NXL Yearly Net Income VS EBIT VS OCF VS FCFNXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

NXL has a Return On Assets of -180.15%. This is amonst the worse of the industry: NXL underperforms 93.12% of its industry peers.
NXL has a worse Return On Equity (-206.95%) than 75.13% of its industry peers.
Industry RankSector Rank
ROA -180.15%
ROE -206.95%
ROIC N/A
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NXL Yearly ROA, ROE, ROICNXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

NXL has a better Gross Margin (78.30%) than 91.53% of its industry peers.
NXL's Gross Margin has improved in the last couple of years.
NXL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
NXL Yearly Profit, Operating, Gross MarginsNXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

7

2. Health

2.1 Basic Checks

NXL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NXL has been increased compared to 1 year ago.
Compared to 5 years ago, NXL has more shares outstanding
There is no outstanding debt for NXL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NXL Yearly Shares OutstandingNXL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NXL Yearly Total Debt VS Total AssetsNXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -15.60, we must say that NXL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -15.60, NXL is doing worse than 86.77% of the companies in the same industry.
NXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.6
ROIC/WACCN/A
WACC9.22%
NXL Yearly LT Debt VS Equity VS FCFNXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

NXL has a Current Ratio of 7.25. This indicates that NXL is financially healthy and has no problem in meeting its short term obligations.
NXL's Current ratio of 7.25 is amongst the best of the industry. NXL outperforms 86.77% of its industry peers.
A Quick Ratio of 6.93 indicates that NXL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.93, NXL belongs to the top of the industry, outperforming 87.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.25
Quick Ratio 6.93
NXL Yearly Current Assets VS Current LiabilitesNXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

5

3. Growth

3.1 Past

NXL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.03%.
Looking at the last year, NXL shows a very strong growth in Revenue. The Revenue has grown by 52.39%.
The Revenue has been decreasing by -4.05% on average over the past years.
EPS 1Y (TTM)-29.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-160%
Revenue 1Y (TTM)52.39%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%31.71%

3.2 Future

NXL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.14% yearly.
Based on estimates for the next years, NXL will show a very strong growth in Revenue. The Revenue will grow by 175.34% on average per year.
EPS Next Y9.84%
EPS Next 2Y10.14%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year74.42%
Revenue Next 2Y175.34%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NXL Yearly Revenue VS EstimatesNXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200K 400K 600K 800K 1M
NXL Yearly EPS VS EstimatesNXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NXL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NXL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NXL Price Earnings VS Forward Price EarningsNXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXL Per share dataNXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.14%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NXL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXALIN TECHNOLOGY INC

NASDAQ:NXL (5/22/2025, 8:00:01 PM)

After market: 1.19 -0.02 (-1.65%)

1.21

+0.01 (+0.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/dmh
Earnings (Next)N/A N/A
Inst Owners2.87%
Inst Owner Change6.04%
Ins Owners18.02%
Ins Owner Change0.18%
Market Cap16.09M
Analysts80
Price Target5.1 (321.49%)
Short Float %1.46%
Short Ratio1.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-110.4%
Min EPS beat(2)-131.02%
Max EPS beat(2)-89.77%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.96%
Min Revenue beat(2)-10.89%
Max Revenue beat(2)18.81%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)66.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 95.39
P/FCF N/A
P/OCF N/A
P/B 4.38
P/tB 4.71
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0.01
BVpS0.28
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -180.15%
ROE -206.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.3%
FCFM N/A
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 354.31%
Cap/Sales 31.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.25
Quick Ratio 6.93
Altman-Z -15.6
F-Score4
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-160%
EPS Next Y9.84%
EPS Next 2Y10.14%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)52.39%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%31.71%
Revenue Next Year74.42%
Revenue Next 2Y175.34%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2.84%
OCF growth 3YN/A
OCF growth 5YN/A